SPATA31D5P

Across TCGA pan-cancer cohorts, SPATA31D5P Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SPATA31D5P data layer compared with 15 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPATA31D5P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA31D5P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, OV, and UCEC are the cancer types where SPATA31D5P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.133	0.796	<.001	36	view →
OV	OS	Median	II,III,IV	0.451	0.693	.022	18	view →
UCEC	DFS	Median	All	0.923	0.607	.012	16	view →
ACC	OS	Median	All	0.158	0.632	.012	9	view →
DLBC	DFS	Median	All	0.022	0.809	<.001	6	view →
LUAD	OS	Median	III,IV	0.237	0.687	.001	6	view →
CESC	DFS	Median	III,IV	0.153	0.636	.013	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	0.107	0.575	<.001	6	view →
READ	DFS	Median	IV	0.255	0.628	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SPATA31D5P–KIRC (DFS)

Open the KIRC breakdown →